Aviva
GBT

Aviva’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Aviva’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,511
Closed -$1.02M – 988
2020
Q4 		$1.02M Sell
23,511
-19,060
-45% -$940K 0.01% 860
2020
Q3 		$2.35M Buy
42,571
+8,226
+24% +$523K 0.01% 655
2020
Q2 		$2.17M Sell
34,345
-36,686
-52% -$2.52M 0.01% 749
2020
Q1 		$3.63M Buy
71,031
+37,028
+109% +$2.48M 0.03% 569
2019
Q4 		$2.7M Buy
+34,003
New +$2.01M 0.02% 604

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aviva's GBT Position: Q1 2021 in Review

Aviva sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 23,511 shares — an estimated $1.02M sold.

Aviva first reported a position in GBT in Q4 2019 and held it in 5 quarters. The position peaked at $3.63M in Q1 2020. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

  • Aviva reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Aviva sold 23,511 Global Blood Therapeutics, Inc. shares in Q1 2021, an estimated $1.02M.
  • Aviva first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 5 quarters.
  • Aviva's Global Blood Therapeutics, Inc. position peaked at $3.63M in Q1 2020.
  • 214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on Aviva's 13F filing for Q1 2021, filed 13 May 2021.